The Health Resources and Services Administration (HRSA) on Oct. 1 continued implementing rebate models for the 340B Drug Pricing Program by approving plans from 10 pharmaceutical manufacturers. The manufacturers cover 18 of 20 products potentially eligible for rebate models in 2027. Pharmaceutical products are eligible for rebates if Medicare payment for the products is negotiated through the Medicare Drug Price Negotiation Program in 2027. Details and the submitted plans are available on HRSA’s website.
Two manufacturers—AstraZeneca, for its cancer drug Calquence, and Novo Nordisk, for Ozempic and its counterparts—declined to submit plans before the September deadline. Four additional products are no longer eligible for negotiation because of statutory provisions related to market competition and generic or biosimilar equivalents. Finally, pharmaceutical manufacturer Bausch exited the 340B program in 2025; as a result, its products are not eligible for Medicaid or Medicare reimbursement.
Along with releasing the manufacturer plans, HRSA updated the rebate model webpage to include FAQ, details on how the agency will evaluate the pilot, and other information about rebate pilot implementation.
Contact Director of Policy Rob Nelb, MPH, at rnelb@essentialhospitals.org or 202.585.0127 with questions.
Author